Results 81 to 90 of about 2,580 (202)

Nuclear protein in testis midline carcinoma presenting in an infant as a pericardial mass with staging by 18F-fluorodeoxyglucose-positron emission tomography/computed tomography

World Journal of Nuclear Medicine, 2017
Nuclear protein in testis (NUT) midline carcinoma (NMC) is a rare, aggressive, lethal, epithelioid, poorly differentiated cancerfirst described in Japan in 1991, unique in that is defined genetically rather than by histological tissue of origin.
Crystal Perkins, Darko Pucar, Colleen McDonough, Hadyn Williams   +3 more
doaj   +1 more source

Primary Thyroid NUT Carcinoma With High PD-L1 Expression and Novel Massive IGKV Gene Fusions: A Case Report With Treatment Implications and Literature Review

Frontiers in Oncology, 2022
BackgroundNuclear protein in testis (NUT) carcinoma (NC) is a rare and aggressive undifferentiated carcinoma that typically arises from midline supradiaphragmatic structures. It is uniquely driven by a NUT gene rearrangement on chromosome 15q14.
Juan Zhou, Miao Duan, Qiong Jiao, Chunyan Chen, Aiyan Xing, Peng Su, Juan Tang, Hui Zhang, Zhiyan Liu   +8 more
doaj   +1 more source

Role of parathyroid hormone therapy in reversing radiation‐induced nonunion and normalization of radiomorphometrics in a murine mandibular model of distraction osteogenesis [PDF]

, 2013
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/101851/1/hed23216 ...
Buchman, Steven R., Chepeha, Douglas B., Deshpande, Sagar, Donneys, Alexis, Gallagher, K. Kelly, Nelson, Noah S., Sarhaddi, Deniz, Tchanque‐fossuo, Catherine N.   +7 more
core   +1 more source

Epigenetic polypharmacology: from combination therapy to multitargeted drugs [PDF]

, 2016
The modern drug discovery process has largely focused its attention in the so-called magic bullets, single chemical entities that exhibit high selectivity and potency for a particular target.
A Anighoro, A Dey, A Ganesan, A Mai, A Nudelman, AF Fliri, B Al-Lazikani, B Knoechel, B Meunier, BC Smith, BC Smith, BC Smith, BE Gryder, C Choudhary, C Corminboeuf, C Liu, C Qian, C Tang, C Yu, C Zwergel, C-W Chen, CM Fillmore, CM Grozinger, CY Fong, D Bixby, D Gallenkamp, D Matei, D Passarella, D Rotili, D Sharma, DA Mele, E Bicaku, E Borretto, E Nicodeme, F Sun, F-W Peng, G Zhang, G-L Chen, GE Winter, GL Verdine, H Patel, HS Bandukwala, HS Takhar, J Fischer, J Lu, J Schneider, J Zhao, J Zuber, J-B Chen, J-F Couture, J-PJ Issa, JC Culhane, JL Avalos, JM Burg, JS Kirk, K Agger, K Chen, K K-p, K Pruitt, K Zhao, KB Daniel, KT Thurn, L Chen, L Chen, LK Gediya, M Buchwald, M De los Santos, M Yang, M Zuo, MA Dawson, MA Dawson, MA Park, MB Poulin, MC Chen, MJ Keiser, MM Singh, MS Finnin, N Geva-Zatorsky, OW Rokhlin, P Anand, P Bamborough, P Filippakopoulos, P Hu, P Hu, P Jones, P Rathert, PA Marks, PK Mazur, PN Munster, Q Wang, R Anand, R Morphy, R Morphy, R Nimmanapalli, R Pereira, R Pili, R Álvarez, RA Copeland, RA Juergens, RL Momparler, S Daujat, S Klimasauskas, S Mahboobi, S Mahboobi, S Zhao, SC Hodawadekar, SJ Atkinson, SS Ng, T Beckers, T Finkel, T Kokkola, T Qiu, T Vaissiere, T-G Lee, TH Luu, TJ Galloway, TM Pitts, W Guerrant, WF Hawse, X Cai, X Cheng, X Sun, X Zhang, Y Ling, Y Zhang, Z Chen   +125 more
core   +1 more source

Primary Pulmonary NUT Carcinoma: A Case Illustration of Therapeutic Challenges and Review of Emerging Targeted Therapies

Case Reports in Oncological Medicine, Volume 2026, Issue 1, 2026.
Background Pulmonary NUT carcinoma is a rare but highly aggressive malignancy with poor prognosis. It typically affects younger patients with no smoking history. Given its rapid progression, it is crucial to consider it as a differential diagnosis in a poorly differentiated thoracic mass to ensure timely diagnosis and management.
Jessica Y. Bae, Xiang Yu Gao, Josephine K. Dermawan, Jessica A. Hellyer, Jose I. Mayordomo   +4 more
wiley   +1 more source

Targeting the epigenetic readers in Ewing Sarcoma inhibits the oncogenic transcription factor EWS/Fli1. [PDF]

, 2016
Ewing Sarcoma is a rare bone and soft tissue malignancy affecting children and young adults. Chromosomal translocations in this cancer produce fusion oncogenes as characteristic molecular signatures of the disease.
Alonso, Alonso, Bhalla, Chicas, Conway, Delattre, Delattre, Denny, Denny, Figg, Ghysdael, Gibson, Helman, Helman, Ilaria, Iwamoto, Iwamoto, Iwamoto, James, Janknecht, Juergens, Jurgens, Kees, Kim, Kim, Kimura, Komori, Kovar, Kovar, Kung, Lee, Lee, Lessnick, Lieb, Lugo, May, May, McKeown, McKeown, Notario, Ory, Rausen, Richter, Rouleau, Staege, Stein, Takei, Toretsky, Triche, Umezawa, Uren, Uren, van den Berg, Young, Young, Young, Zhou   +56 more
core   +2 more sources

Monotherapy With Immune Checkpoint Inhibitors in Patients With Recurrent and/or Metastatic Sinonasal Squamous Cell Carcinoma

Cancer Medicine, Volume 14, Issue 23, December 2025.
ABSTRACT Introduction Sinonasal squamous cell carcinoma (SNSCC) is a rare malignancy with limited data on effective treatment modalities in the recurrent and/or metastatic (r/m) setting. While immune checkpoint inhibitors (ICIs) have shown promise in treating head and neck cancers, in general, their effects in SNSCC remain poorly understood ...
Alexander Lein, Thorsten Fuereder, Manuel Stoeth, Agmal Scherzad, Stephan Hackenberg, Julia Schnöll, Lorenz Kadletz‐Wanke, Gregor Heiduschka, Archana Jaiswal, Rajiv Bhalla, Lukas Kenner, Faris F. Brkic   +11 more
wiley   +1 more source

Diagnosis, Treatment and Prognosis of Primary Pulmonary NUT Carcinoma: A Literature Review

Current Oncology, 2022
NUT carcinoma is a rare, highly lethal cancer characterized with the rearrangement of the nuclear protein in testis (NUT) gene on chromosome 15q14, which primarily occurs in the midline organs.
Jiaqian Yuan, Zhili Xu, Yong Guo
doaj   +1 more source

Discovery and optimization of a selective ligand for the switch/sucrose nonfermenting-related bromodomains of polybromo protein-1 by the use of virtual screening and hydration analysis [PDF]

, 2016
Bromodomains (BRDs) are epigenetic interaction domains currently recognized as emerging drug targets for development of anticancer or anti-inflammatory agents.
Bagratuni, Tina, Brownlee, Peter Moore, Downs, Jessica Ann, Drosos, Nikolaos, Fedorov, Oleg, Filippakopoulos, Panagis, Gaboriaud-Kolar, Nicolas, Grigoriou, Stylianos, Hall, Michelle-Lynn, Heidenreich, David, Kastritis, Efstathios, Knapp, Stefan, Mexia, Nikitia, Mikros, Emmanuel, Myrianthopoulos, Vassilios, Müller, Susanne, Rogers, Catherine, Savitsky, Pavel, Skaltsounis, Alexios-Leandros, Tallant, Cynthia, Terpos, Evangelos, Wanior, Marek   +21 more
core   +4 more sources

A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS Tumors

Cancer Medicine, Volume 14, Issue 23, December 2025.
ABSTRACT Background Fimepinostat, an oral dual inhibitor of histone deacetylase (HDAC) and phosphatidylinositol‐4,5‐bisphosphate 3‐kinase (PI3K), has shown activity in preclinical models of Myc‐driven pediatric malignancies. This Phase 1 trial aimed to determine the recommended pediatric Phase 2 dose (RPP2D), describe the toxicity profile, and evaluate
David S. Shulman, Kieuhoa T. Vo, Frank M. Balis, Holly Lindsay, Rochelle Bagatell, Andrew E. Place, Susan N. Chi, Suzanne Shusterman, Suzanne Ezrre, Jeffrey Czaplinski, Ketki Bhushan, Pei‐Chi Kao, Wendy B. London, Steven G. DuBois   +13 more
wiley   +1 more source